Form 4: Y-mAbs Therapeutics Director Sells Shares to Cover Tax Obligations

Gerard Ber, a director of Y-mAbs Therapeutics, sold 722 shares of common stock on June 10, 2024, to cover tax liabilities associated with the vesting and settlement of restricted stock units.

Summary

• On June 10, 2024, Gerard Ber, a director of Y-mAbs Therapeutics, sold 722 shares of the company's common stock.
• The sale was executed to cover tax liabilities related to the vesting and settlement of restricted stock units.
• The shares were sold at a weighted average price of $12.00, with individual trades ranging from $12.00 to $12.015.
• Following the transaction, Ber directly owns 1,608 shares of Y-mAbs Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Sales of shares by company insiders are a common occurrence, often related to compensation or personal financial planning. It's important to consider the context of these sales, such as the reason for the sale and the overall trend of insider transactions.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the reason for the sale.

Key Dates